WO2023205914 - TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2023/205914
Publication Date
02.11.2023
International Application No.
PCT/CN2022/000075
International Filing Date
28.04.2022
Title **
[English]
TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
[French]
DÉRIVÉS HÉTÉROCYCLIQUES TRICYCLIQUES, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
Applicants **
DANATLAS PHARMACEUTICALS CO., LTD.
Suite 101, Floor 2, Building 4, Area 7-2, Liangshuihe 1st Street, BDA
Beijing 100176, CN
Inventors
YU, Zhangqi
Suite 502, Building 33-B, 99 Kechuang 14th Street, BDA
Beijing 100176, CN
YAN, Dan
Suite 502, Building 33-B, 99 Kechuang 14th Street, BDA
Beijing 100176, CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2626 | |
| EPO | Filing, Examination | 25118 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 12110 |
Total: 40924 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.[French]
L'invention concerne des dérivés hétérocycliques tricycliques tels que représentés dans la formule (I), des compositions pharmaceutiques les comprenant, un procédé pour leur préparation et leur utilisation en tant qu'agents thérapeutiques.